Charles Elliott Sigal - 03 Jul 2023 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Reporting relationship: Director
Issuer ticker: ADAP
Reported as of: 03 Jul 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jul 2023, 17:02:43 UTC
Prior SEC filing: 24 May 2023
Next SEC filing: 08 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Charles Elliott Sigal

Key filing fact

Charles Elliott Sigal filed Form 4 for Adaptimmune Therapeutics PLC (ADAP) on 03 Jul 2023.

Key facts

This page summarizes Charles Elliott Sigal's Form 4 filing for Adaptimmune Therapeutics PLC (ADAP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jul 2023, 17:02.

Change

Previous filing in this sequence was filed on 24 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADAP transaction Derivative

Option to purchase Ordinary Shares

Award

Transaction value: $0
Shares: +933,317
Change %
Price: $0.000000
Shares after: 933,317
Date: 03 Jul 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 933,317
Exercise price: $0.1600
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.